Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Spectral AI Inc.(MDAI)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MDAI
11/11/2026: MDAI (1-star) is currently NOT-A-BUY. Pass it for now.
Spectral AI Inc. is a development-stage medical technology company focused on AI-powered wound diagnostics. The company’s core value lies in its DeepView system, which aims to provide real-time, non-invasive assessment of burn tissue viability. While the company holds a potential first-mover advantage in AI-driven wound care and has achieved positive regulatory milestones, it currently generates minimal revenue and faces significant execution, cash burn, and competitive risks. Spectral AI is best suited for risk-tolerant, growth-oriented investors who monitor regulatory and clinical updates closely. The primary investment story rests on successful FDA clearance and eventual broad clinical adoption, rather than existing profitability or current income.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-growth potential driven by its AI technology, but this is tempered by significant execution and regulatory risks. |
| Momentum investor | Strong fit while signal remains positive | The stock can exhibit significant price movement based on news regarding clinical trials or regulatory updates. |
| Value investor | Weak fit | The company is in an early, loss-making phase and lacks the traditional earnings or cash flow metrics favored by value investors. |
| Dividend investor | Weak fit | Spectral AI does not pay a dividend and focuses on cash preservation for growth. |
| Low-risk investor | Weak fit | The high volatility, development-stage risks, and reliance on regulatory approval make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to large price swings driven by clinical or regulatory outcomes. |
| Valuation risk | High | As a speculative growth stock, valuations are often based on future projections rather than current fundamentals. |
| Competition risk (AI diagnostic competition) | Medium / high | Established incumbents could develop or acquire competing AI technology to displace DeepView. |
| Business quality | Medium | While the technology is innovative, the company is still establishing its operational and commercial track record. |
| Dividend income | Low / none | No income component is provided to investors. |
| Execution risk | High | The ability to successfully move from clinical research to commercial profitability is uncertain and difficult. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -26.71% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/11/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Sector & Industry Intelligence
Sector snapshot as of 2026-11-10
Sector
Healthcare
- Signal
- Constructive
- Sentiment
- Strong Bullish
- Market state
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 60.0%
- Active BUY / eligible
- 69 / 115
- 22-session BUY-count change
- +29
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Medical Devices
- BUY participation
- 57.1%
- Active BUY / eligible
- 4 / 7
- 22-session BUY-count change
- +1
The sector signal does not change this stock’s BUY, SELL, or PASS advisory.
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 49.56M USD | Price to earnings Ratio - | 1Y Target Price 5.11 |
Price to earnings Ratio - | 1Y Target Price 5.11 | ||
Volume (30-day avg) 141.3K shares | Beta 1.25 | 52 Weeks Range 1.18 - 2.97 | Updated Date 11/10/2026 |
52 Weeks Range 1.18 - 2.97 | Updated Date 11/10/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.32 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Diagnostic Technology | Future sales, licensing, or recurring revenue models related to the DeepView system. | Revenue will depend on the successful regulatory approval and widespread adoption of the company's AI medical imaging devices. |
Valuation
Trailing PE - | Forward PE 52.36 | Enterprise Value 51.52M | Price to Sales(TTM) 3.22 |
Enterprise Value 51.52M | Price to Sales(TTM) 3.22 | ||
Enterprise Value to Revenue 3.35 | Enterprise Value to EBITDA -3.41 | Shares Outstanding 32.18M | Shares Floating 27.87M |
Shares Outstanding 32.18M | Shares Floating 27.87M | ||
Percent Insiders 13.42 | Percent Institutions 19.3 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.